If you need any help or a chat then IM/PM or email me, Chip

Author Topic: Alarming surge in drug-resistant HIV uncovered  (Read 1050 times)

Offline Chip (OP)

  • Server Admin
  • Hero Member
  • *****
  • Administrator
  • *****
  • Join Date: Dec 2014
  • Location: Australia
  • Posts: 6333
  • Reputation Power: 0
  • Chip has hidden their reputation power
  • Gender: Male
  • Last Login:Yesterday at 06:33:11 AM
  • Deeply Confused Learner
  • Profession: IT Engineer
Alarming surge in drug-resistant HIV uncovered
« on: September 06, 2019, 07:27:12 PM »
source: https://www.nature.com/articles/d41586-019-02316-x

Alarming surge in drug-resistant HIV uncovered

30 JULY 2019

The drug-resistant form of the virus has been detected at unacceptable levels across Africa, Asia and the Americas.

Antiretroviral drugs stop HIV from replicating in the body.

Health authorities have uncovered an alarming surge in resistance to crucial HIV drugs.

Surveys by the World Health Organization (WHO) reveal that, in the past 4 years, 12 countries in Africa, Asia and the Americas have surpassed acceptable levels of drug resistance against two drugs that constitute the backbone of HIV treatment: efavirenz and nevirapine.

People living with HIV are routinely treated with a cocktail of drugs, known as antiretroviral therapy, but the virus can mutate into a resistant form.

The WHO conducted surveys from 2014 to 2018 in randomly selected clinics in 18 countries, and examined the levels of resistance in people who had started HIV treatment during that period.

More than 10% of adults with the virus have developed resistance to these drugs in 12 nations (see ‘Resistance rises’). Above this threshold, it’s not considered safe to prescribe the same HIV medicines to the rest of the population, because resistance could increase. Researchers published the findings this month in WHO report.

“I think we have kind of crossed the line,” says Massimo Ghidinelli, an infectious-disease specialist at the Pan American Health Organization in Washington DC.

Overall, 12% of women surveyed had a drug-resistant form of HIV, compared with 8% of men.

Particularly concerning, says the report, is the high level of resistance in infants with HIV in sub-Saharan Africa. Between 2012 and 2018, about one-half of newly diagnosed infants in nine of the countries in this region had a form of HIV that was resistant to efavirenz, nevirapine or both.

The causes of drug resistance remain elusive, says Silvia Bertagnolio, an infectious-disease physician at the WHO in Geneva, Switzerland, and co-author of the report. But drug-resistant HIV might develop when people interrupt treatment, she suggests.

For example, many women living with the virus might have taken antiretrovirals during pregnancy to prevent their babies from becoming infected, but stopped after delivery. The WHO recommended this practice until 2015, when it suggested that pregnant and breastfeeding women use the drugs for life.

The prevalence of resistance in people who restarted efavirenz and nevirapine after interrupting treatment was much higher (21%) than in first-time users (8%).

People living with HIV might go on and off the drugs for several reasons. Stigma plays a huge part, says Bertagnolio; they might not want to be seen picking up their medicines. Drug shortages at clinics could also contribute, the report noted.

In response to the evidence, the WHO has recommended that countries use dolutegravir, which is more effective and tolerable than other therapies, as the go-to HIV drug. The likelihood that the virus will develop mutations and, eventually, resistance is lower with dolutegravir than with other antiretrovirals, says Roger Paredes, an infectious-disease physician at the Germans Trias i Pujol University Hospital in Barcelona, Spain. “We have to encourage a worldwide transition to dolutegravir,” he adds.

Bertagnolio agrees, but calls for caution. If treatment delivery is poor or patchy, resistance could emerge. “We don’t want to find ourselves in the same situation we’re in.”
I do not condone or support any illegal activities. All information is for theoretical discussion and wonder.
All activities discussed are considered fictional and hypothetical. Information of all discussion has been derived from online research and in the spirit of personal Freedom.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post July 21, 2015, 09:59:49 AM
by Chip
0 Replies
Last post July 22, 2015, 07:51:56 AM
by candy
8 Replies
Last post November 20, 2015, 12:33:11 PM
by Daughter of Dionysus
2 Replies
Last post July 29, 2015, 01:10:34 PM
by Narkotikon
10 Replies
Last post November 14, 2015, 01:46:17 PM
by Daughter of Dionysus
2 Replies
Last post January 17, 2016, 05:04:39 PM
by smalls
2 Replies
Last post June 07, 2016, 06:49:43 PM
by Chip
2 Replies
Last post September 27, 2016, 08:03:06 PM
by Chip
5 Replies
Last post September 30, 2016, 03:04:44 AM
by Tainted
0 Replies
Last post October 20, 2019, 01:21:12 PM
by andrew


In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


Founded December 2014
SimplePortal 2.3.6 © 2008-2014, SimplePortal